New guidelines from the NCCN for polycythemia vera.
作者信息
Mesa Ruben A
机构信息
University of Texas Health Science Center, San Antonio, Texas.
出版信息
Clin Adv Hematol Oncol. 2017 Nov;15(11):848-850.
Abstract
摘要
相似文献
1
New guidelines from the NCCN for polycythemia vera.美国国立综合癌症网络（NCCN）发布的真性红细胞增多症新指南。
Clin Adv Hematol Oncol. 2017 Nov;15(11):848-850.
2
Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?真性红细胞增多症或原发性血小板增多症患者均需要细胞减少治疗吗？
J Natl Compr Canc Netw. 2018 Dec;16(12):1539-1545. doi: 10.6004/jnccn.2018.7073.
3
From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?从水蛭到干扰素：真性红细胞增多症患者都应接受细胞减灭治疗吗？
Leukemia. 2020 Nov;34(11):2837-2839. doi: 10.1038/s41375-020-0984-9. Epub 2020 Jul 16.
4
[Polycythemia vera: the disadvantages of overproduction].
MMW Fortschr Med. 2015 Apr 30;157(8):18-20. doi: 10.1007/s15006-015-3012-7.
5
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.接受羟基脲治疗的真性红细胞增多症患者中，根据放血需求评估的血栓形成风险。
Haematologica. 2017 Jan;102(1):103-109. doi: 10.3324/haematol.2016.152769. Epub 2016 Sep 29.
6
Treatment target in polycythemia vera.真性红细胞增多症的治疗目标。
N Engl J Med. 2013 Apr 18;368(16):1555-6. doi: 10.1056/NEJMc1301262.
7
Treatment target in polycythemia vera.真性红细胞增多症的治疗目标。
N Engl J Med. 2013 Apr 18;368(16):1554-5. doi: 10.1056/NEJMc1301262.
8
Treatment target in polycythemia vera.真性红细胞增多症的治疗目标
N Engl J Med. 2013 Apr 18;368(16):1555. doi: 10.1056/NEJMc1301262.
9
Treatment target in polycythemia vera.真性红细胞增多症的治疗目标。
N Engl J Med. 2013 Apr 18;368(16):1556-7. doi: 10.1056/NEJMc1301262.
10
Treatment target in polycythemia vera.真性红细胞增多症的治疗目标。
N Engl J Med. 2013 Apr 18;368(16):1556. doi: 10.1056/NEJMc1301262.
引用本文的文献
1
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.探索真性红细胞增多症的血栓栓塞危险因素：从当前证据到PROSPERO研究设计
Ann Hematol. 2025 Jul 18. doi: 10.1007/s00277-025-06466-z.
2
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study.真性红细胞增多症高危患者一线治疗反应欠佳后改用鲁索替尼与未改用者的临床结局：PV-Switch研究结果
Ther Adv Hematol. 2025 Jul 4;16:20406207251342199. doi: 10.1177/20406207251342199. eCollection 2025.
3
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.识别羟基脲起始治疗后有血栓形成风险的真性红细胞增多症患者：真性红细胞增多症-高级综合模型（PV-AIM）项目
Biomedicines. 2023 Jul 7;11(7):1925. doi: 10.3390/biomedicines11071925.
4
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.骨髓增殖性肿瘤的遗传图谱，重点关注分子诊断实验室检测
Life (Basel). 2021 Oct 30;11(11):1158. doi: 10.3390/life11111158.
5
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.聚乙二醇化干扰素α-2b 联合利巴韦林治疗慢性丙型肝炎的疗效和安全性：一项多中心、随机、对照研究
Blood Cancer J. 2021 Mar 6;11(3):53. doi: 10.1038/s41408-021-00445-z.
6
Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study.羟基脲处方和使用模式在真性红细胞增多症常规临床管理中的研究：一项多中心图表回顾研究。
Turk J Haematol. 2020 Aug 28;37(3):177-185. doi: 10.4274/tjh.galenos.2020.2019.0431. Epub 2020 Feb 20.
7
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.givinostat最大耐受剂量在真性红细胞增多症中的安全性和有效性：一项两部分的Ib/II期研究。
Leukemia. 2020 Aug;34(8):2234-2237. doi: 10.1038/s41375-020-0735-y. Epub 2020 Feb 11.
本文引用的文献
1
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.芦可替尼治疗无脾肿大的未充分控制的真性红细胞增多症（RESPONSE-2）：一项随机、开放标签、3b 期研究。
Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.
2
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.鲁索替尼对比最佳可用疗法治疗真性红细胞增多症患者：RESPONSE试验80周随访结果
Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21.
3
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.芦可替尼与标准疗法治疗真性红细胞增多症的对比
N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
Zotero 插件